{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:09:14Z","timestamp":1791896954586,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00277-016-2878-5","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T07:10:34Z","timestamp":1480489834000},"page":"253-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone"],"prefix":"10.1007","volume":"96","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Dimier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wassner-Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"Launonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"2878_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 89:3909\u20133918","journal-title":"Blood"},{"key":"2878_CR2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, W\u04e7rmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Tr\u00fcmper L, Aldaoud A, Parwaresch R, Unterlalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"2878_CR3","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-C\u00e9ligny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579\u20134586","journal-title":"J Clin Oncol"},{"key":"2878_CR4","doi-asserted-by":"crossref","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, H\u00e4nel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, B\u00f6ck HP, Wandt H, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 104:3064\u20133071","DOI":"10.1182\/blood-2004-04-1323"},{"key":"2878_CR5","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van\u2019t Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108:3295\u20133301","journal-title":"Blood"},{"key":"2878_CR6","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/cncr.25603","volume":"117","author":"C Nabhan","year":"2011","unstructured":"Nabhan C, Davis N, Bitran JD, Galvez A, Fried W, Tolzien K, Foss S, Dewey WM, Venugopal P (2011) Efficacy and safety of clofarabine in relapsed and\/or refractory non-hodgkin lymphoma, including rituximab-refractory patients. Cancer 117:1490\u20131497","journal-title":"Cancer"},{"key":"2878_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayed LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204\u2013210","journal-title":"J Clin Oncol"},{"key":"2878_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"BS Kahl","year":"2010","unstructured":"Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116:106\u2013114","journal-title":"Cancer"},{"key":"2878_CR9","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","volume":"119","author":"G Salles","year":"2012","unstructured":"Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Askanius E, Carlile D, Birkett J, Pisa P, Cartron G (2012) Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119:5126\u20135132","journal-title":"Blood"},{"key":"2878_CR10","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","volume":"31","author":"G Salles","year":"2013","unstructured":"Salles G, Morschhauser F, Solal-C\u00e9ligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G (2013) Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 31:2920\u20132926","journal-title":"J Clin Oncol"},{"key":"2878_CR11","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW (2015) Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 33:3467\u20133474","journal-title":"J Clin Oncol"},{"key":"2878_CR12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD (2016) A randomised controlled trial of obinutuzumab plus bendamustine versus bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: primary results of the GADOLIN study. Lancet Oncol 17:1081\u20131093","journal-title":"Lancet Oncol"},{"key":"2878_CR13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","volume":"19","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJ, Rule S, Walker M, Wild D (2008) The impact of follicular lymphoma on health-related quality of life. Ann Oncol 19:570\u2013576","journal-title":"Ann Oncol"},{"key":"2878_CR14","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cncr.24391","volume":"115","author":"SK Smith","year":"2009","unstructured":"Smith SK, Zimmerman S, Williams CS, Zebrack BJ (2009) Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 115:3312\u20133323","journal-title":"Cancer"},{"key":"2878_CR15","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1200\/JCO.2005.03.343","volume":"23","author":"TA Ahles","year":"2005","unstructured":"Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Titus-Ernstoff L, Skalla K, Bakitas M, Silberfarb PM (2005) Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 23:4399\u20134405","journal-title":"J Clin Oncol"},{"key":"2878_CR16","unstructured":"Webster K, Cashy J, Cella D (2005) Measuring quality of life (QOL) in patients with non-Hodgkin\u2019s lymphoma (NHL): the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM). Qual Life Res 14(9) (abstract 1650)"},{"key":"2878_CR17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood.V106.11.750.750","volume":"106","author":"D Cella","year":"2005","unstructured":"Cella D, Webster K, Cashy J, Kutikova L, Burgess MF, Lin BK, Bowman L, Liepa AM, Gauthier JE, Gregory SA, Johnson SA, Cheson BD (2005) Development of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma clinical research: the functional assessment of cancer therapy-lymphoma (FACT-Lym). Blood 106:750 (abstract 750)","journal-title":"Blood"},{"key":"2878_CR18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.V112.11.828.828","volume":"112","author":"GC Carter","year":"2008","unstructured":"Carter GC, Liepa AM, Zimmerman AH, Morschhauser F (2008) Validation of the functional assessment of cancer therapy-lymphoma (FACT-Lym) in patients with relapsed\/refractory mantle cell lymphoma. Blood 112:828 (abstract 2376)","journal-title":"Blood"},{"key":"2878_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health and Quality of Life Outcomes 1:79","journal-title":"Health and Quality of Life Outcomes"},{"key":"2878_CR20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pon.1428","volume":"18","author":"M Janda","year":"2009","unstructured":"Janda M, DiSipio T, Hurst C, Cella D, Newman B (2009) The Queensland Cancer Risk Study: general population norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Psychooncology 18:606\u2013614","journal-title":"Psychooncology"},{"key":"2878_CR21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11764-009-0106-1","volume":"4","author":"CM Crespi","year":"2010","unstructured":"Crespi CM, Smith SK, Petersen L, Zimmerman S, Ganz PA (2010) Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors. J Cancer Surviv 4:45\u201358","journal-title":"J Cancer Surviv"},{"key":"2878_CR22","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3109\/10428194.2014.894190","volume":"55","author":"HJ Olney","year":"2014","unstructured":"Olney HJ, Freeman MA, Stewart DA, Mangel JE, White DJ, Elia-Pacitti JO (2014) Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma. Leuk Lymphoma 55:2754\u20132760","journal-title":"Leuk Lymphoma"},{"key":"2878_CR23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00277-014-2269-8","volume":"94","author":"MS Czuczman","year":"2015","unstructured":"Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N (2015) Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin\u2019s lymphoma. Ann Hematol 94:633\u2013641","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2878-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2878-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2878-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T21:57:02Z","timestamp":1718920622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2878-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2878"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2878-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}